Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg bumps up target price on Rightmove

(Sharecast News) - Analysts at Berenberg raised their target price on Rightmove from 775.0p to 795.0p on Tuesday following the group's FY24 results last week. Berenberg noted that Rightmove's share price has increased by roughly 9% since its FY24 results, outperforming the FTSE All-Share by around 7%.

The German bank thinks that the key takeaways from Rightove's results were that the core business continued to "perform well" and was seemingly unaffected by rival CoStar's entry into the market, that its strategic growth areas were operationally on track and that its FY25 outlook pointed to an acceleration in revenue growth.

Berenberg also introduced FY27 forecasts on Rightmove for the first time, which implies 10% revenue growth and an underlying EBIT margin of 70%.

"Rightmove's shares have increased by 22% over the past 12 months and the shares have re-rated by 9% to 23.3x on a 12-month forward price-to-earnings basis. We increase our price target to 795p (from 775p), which reflects the mechanical update of our DCF and forecasts," said Berenberg, which reiterated its 'buy' rating on the stock.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.